A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking

Trial Profile

A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Nicotine abuse vaccine (Primary)
  • Indications Smoking withdrawal; Substance-related disorders
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2008 Planned end date changed from 1 Oct 2007 to 1 Nov 2008, based on information from ClinicalTrials.gov.
    • 03 May 2007 Status changed from initiated to in progress.
    • 08 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top